Elite Journal of Immunology. Volume 2 Issue 6(2024), Pp. 26-43
https://epjournals.com/journals/EJI

Malaria in Pregnancy: Insights into Immunological Responses

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.
[2]School of Nursing Science, Kampala International University, Ishaka, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Malaria during pregnancy poses significant health risks to both the mother and the fetus, particularly in regions endemic to Plasmodium falciparum. The altered immune system of pregnant women, essential for fetal tolerance, also increases susceptibility to malaria infection, leading to severe complications such as maternal anemia, placental malaria, low birth weight, and preterm delivery. This review delves into the immunological responses to malaria during pregnancy, exploring the interplay between the parasite and the maternal immune system, and examining the resultant impacts on maternal and fetal health. Key areas of focus include the modulation of cytokine profiles, immune evasion strategies of Plasmodium falciparum, and the immune responses specific to placental malaria. Pregnancy induces substantial immunological changes, including shifts in cytokine production and immune cell populations, which create a more anti-inflammatory environment to prevent fetal rejection. These changes can impair the mother's ability to effectively respond to infections, including malaria. Plasmodium falciparum exploits these immune alterations through mechanisms such as the expression of VAR2CSA, which facilitates the adhesion of infected erythrocytes to the placenta, thus evading immune clearance. Public health interventions that incorporate an understanding of these immunological dynamics are crucial for mitigating the impact of malaria in pregnancy. Strategies such as intermittent preventive treatment, the use of insecticide-treated bed nets, and the development of vaccines targeting specific antigens like VAR2CSA are essential.

Keywords*: Malaria, pregnancy, immunological responses, Plasmodium falciparum, placental malaria, cytokines, immune evasion, maternal immunity*

Introduction

Citation: Obeagu EI, Obeagu GU. Malaria in Pregnancy: Insights into Immunological Responses**.** Elite Journal of Immunology, 2024; 2(6): 26-43

Malaria remains a global health challenge, with a particularly severe impact on pregnant women and their unborn children. Plasmodium falciparum, the most dangerous of the malaria parasites, poses substantial risks during pregnancy, including maternal anemia, low birth weight (LBW), preterm delivery, and increased perinatal mortality. The immunological responses of pregnant women to malaria are unique and complex, involving interactions between the parasite and the maternal immune system that can lead to severe disease outcomes. Pregnancy induces significant immunological changes in women, driven by the need to tolerate the semi-allogeneic fetus while still defending against infections. This immunomodulation includes alterations in cytokine production, immune cell populations, and the balance between pro-inflammatory and anti-inflammatory responses. While these changes help prevent fetal rejection, they can also make pregnant women more susceptible to infections like malaria. The immune system's delicate balance during pregnancy is a critical aspect of the host-parasite interaction in malaria. Plasmodium falciparum has evolved sophisticated mechanisms to exploit the altered immune environment of pregnancy. One of the primary strategies involves the expression of variant surface antigens, such as VAR2CSA, on the surface of infected erythrocytes. These antigens facilitate the adhesion of the erythrocytes to the placental syncytiotrophoblasts, creating a reservoir of infection in the placenta. This adhesion helps the parasite evade immune clearance and establishes a chronic infection that can lead to severe complications for both the mother and the fetus. Cytokines play a pivotal role in the immune response to malaria during pregnancy. Pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ), are associated with protective immune responses against malaria but can also contribute to adverse pregnancy outcomes like preterm delivery and LBW. Conversely, anti-inflammatory cytokines, such as interleukin-10 (IL-10), help mitigate excessive inflammation but may impair the clearance of parasites. The balance between these cytokines is crucial in determining the outcome of malaria in pregnancy.[1-10]

Placental malaria, characterized by the accumulation of infected erythrocytes in the placenta, is a significant concern. This condition leads to inflammation and impaired placental function, which can adversely affect fetal growth and development. The immune response in the placenta involves a complex interplay of various immune cells, including macrophages, dendritic cells, and T cells. These cells produce cytokines and chemokines that can either control the infection or contribute to placental damage, highlighting the complexity of the immune responses involved. Maternal immunity to malaria evolves with parity and previous exposure to the parasite. Women in their first pregnancy (primigravidae) are more susceptible to malaria compared to women with multiple pregnancies (multigravidae), who typically have better immune responses due to the acquisition of specific antibodies targeting placental parasites. These antibodies prevent the adhesion of infected erythrocytes to the placenta and enhance parasite clearance, demonstrating the importance of adaptive immunity in mitigating the effects of malaria in pregnancy. Public health interventions targeting malaria in pregnancy must consider these immunological dynamics. Interventions such as intermittent preventive treatment in pregnancy (IPTp) with antimalarial drugs, the use of insecticide-treated bed nets (ITNs), and prompt diagnosis and treatment are crucial for protecting pregnant women from malaria. These strategies not only reduce the incidence of malaria but also improve maternal and fetal health outcomes. Understanding the immunological basis of these

interventions can enhance their effectiveness and inform the development of new strategies. The development of vaccines targeting specific antigens, such as VAR2CSA, represents a promising approach to prevent placental malaria. These vaccines aim to induce robust immune responses that prevent the adhesion of infected erythrocytes to the placenta, thereby reducing the risk of chronic infection and its associated complications. Additionally, strategies to modulate cytokine responses could help balance the need for effective parasite clearance with the prevention of inflammation-related adverse outcomes. Despite significant progress in understanding the immunological aspects of malaria in pregnancy, several challenges remain. The variability in immune responses among different populations and the impact of co-infections and other health conditions complicate the development of universal interventions. Further research is needed to elucidate the mechanisms underlying immune modulation during pregnancy and to identify biomarkers for predicting disease severity and treatment outcomes. Integrating immunological insights into public health strategies will be crucial for reducing the burden of malaria in pregnancy.[11-20]

Immunological Changes During Pregnancy

Pregnancy represents a unique physiological state characterized by substantial immunological changes designed to ensure the protection of both the mother and the fetus. These changes are crucial for maintaining the balance between maternal immune tolerance and effective defense against infections. One of the primary goals of the maternal immune system during pregnancy is to establish tolerance to the semi-allogeneic fetus, which is genetically distinct from the mother. This process involves several adaptive changes to the immune system. Tolerance mechanisms include alterations in cytokine production, shifts in immune cell populations, and changes in the expression of immune receptors. A notable change is the increased production of anti-inflammatory cytokines, such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), which help mitigate maternal immune responses against fetal antigens. Pregnancy also involves the expansion of regulatory T cells (Tregs), which play a crucial role in maintaining immune tolerance by suppressing excessive inflammatory responses. Tregs are involved in the prevention of fetal rejection and the modulation of maternal immune responses to infections. Their increased presence during pregnancy helps to balance the immune response and prevent the potential harm that could result from an overactive immune system.[21-25]

The cytokine milieu of pregnant women shifts from a predominantly pro-inflammatory profile towards a more anti-inflammatory one. This change is essential for protecting the fetus but can also impact the maternal immune response to infections. For instance, pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) are reduced, while anti-inflammatory cytokines like IL-10 and IL-4 are elevated. This shift can influence the body's ability to mount an effective response to pathogens such as Plasmodium falciparum, the parasite responsible for malaria. The altered cytokine profile during pregnancy can affect various aspects of the immune response, including the function of macrophages, dendritic cells, and T cells. The reduced production of pro-inflammatory cytokines may limit the effectiveness of the immune response against malaria, while an increased anti-inflammatory response can potentially impair the clearance of the parasite. Pregnancy also induces changes in the populations and functions of

immune cells. For example, there is an increase in the number of circulating monocytes and changes in their activation status. These monocytes can differentiate into macrophages that play a role in immune surveillance and pathogen clearance. Additionally, there is a shift in the balance between different T cell subsets, with a relative increase in Tregs and a decrease in Th1 cells, which are typically involved in strong inflammatory responses. Natural killer (NK) cells, which play a role in the innate immune response, also undergo functional changes during pregnancy. While their numbers may increase, their activity can be modulated to ensure they do not cause damage to the fetus. This modulation can impact the body's ability to respond to infections, including malaria. Changes in the activity and function of NK cells can influence the overall immune landscape during pregnancy and affect the outcome of infections.[26-30]

The immunological changes during pregnancy have important implications for the susceptibility and severity of malaria. The shift towards an anti-inflammatory immune environment can reduce the effectiveness of the maternal immune response against Plasmodium falciparum, leading to increased susceptibility to infection. Additionally, the altered cytokine profile and immune cell functions can influence the progression and outcomes of malaria, including the development of placental malaria. Placental malaria is a specific concern in pregnant women, as it involves the accumulation of infected erythrocytes in the placenta, leading to inflammation and impaired placental function. The immune changes during pregnancy can affect the development of placental malaria and its associated complications, such as low birth weight and preterm delivery. *Plasmodium falciparum*, the most virulent of the malaria parasites, has evolved several sophisticated strategies to evade the host immune system. These mechanisms are crucial for the parasite's survival and replication, particularly in the challenging environment of the human host. The ability of *P. falciparum* to evade immune detection and destruction has significant implications for the progression and severity of malaria, especially during pregnancy. One of the primary immune evasion strategies of *P. falciparum* involves the expression of variant surface antigens (VSAs) on the surface of infected erythrocytes. These VSAs are encoded by a family of genes that undergo antigenic variation, meaning that the parasite can change the surface proteins expressed on infected red blood cells (RBCs) over time. This antigenic variation allows *P. falciparum* to evade immune recognition and clearance by the host's adaptive immune system. For instance, the VAR2CSA antigen is specifically expressed in the placental infection, allowing the parasite to adhere to the placental tissue and avoid immune surveillance.[31-35]

Plasmodium falciparum infected RBCs can adhere to various host tissues, including the endothelium of blood vessels and the placental syncytiotrophoblasts. This adhesion is mediated by interactions between VSAs and host receptors, such as chondroitin sulfate A (CSA) in the placenta. By adhering to these tissues, the parasite avoids being cleared by the spleen, which is responsible for filtering and destroying abnormal or infected RBCs. This sequestration in tissues is a critical strategy for the parasite, as it helps maintain a reservoir of infection and contributes to the persistence of malaria in the host. *Plasmodium falciparum* can modulate the host's immune response to facilitate its survival. The parasite can alter the production of cytokines and other immune mediators, influencing the overall immune environment. For example, *P. falciparum* infection can lead to increased production of anti-inflammatory cytokines like IL-10, which can

dampen the pro-inflammatory responses that are necessary for effective parasite clearance. This modulation can impair the host's ability to mount a robust immune response and contribute to the chronicity and severity of the infection. The antigenic variation exhibited by *P. falciparum* also impacts the development of immune memory. As the parasite constantly changes its surface antigens, it prevents the host from developing long-lasting immunity. Even if the host mounts an immune response against one variant of the antigen, subsequent infections with different variants can occur. This continuous cycle of antigenic variation means that the immune system is perpetually engaged in a battle with a moving target, making it challenging to develop effective, long-term immunity. During pregnancy, the immune evasion strategies of *P. falciparum* are further complicated by the altered immune environment. Pregnancy-induced immune changes, including shifts in cytokine production and immune cell populations, can affect the maternal immune response to malaria. The adherence of infected RBCs to the placenta and the resultant placental malaria can lead to localized immune responses that may not be effective in clearing the infection. This localized immune response, combined with the general systemic immune suppression during pregnancy, creates a conducive environment for the parasite's persistence and contributes to adverse pregnancy outcomes.[36-45]

The immune evasion mechanisms of *P. falciparum* also have implications for the efficacy of antimalarial treatments. The parasite's ability to sequester in tissues can limit the reach of antimalarial drugs that are primarily effective in the bloodstream. Additionally, *P. falciparum* has developed resistance mechanisms to several antimalarial drugs, further complicating treatment efforts. The combination of immune evasion and drug resistance underscores the need for new and effective treatment strategies to combat malaria. *P. falciparum* can directly interact with various host immune cells, including macrophages, dendritic cells, and T cells, to further evade immune detection. The parasite can manipulate the function of these cells to its advantage. For instance, infected RBCs can inhibit the activation of macrophages and dendritic cells, reducing their ability to present antigens and activate T cells. This interference with antigen presentation can impair the development of an effective adaptive immune response. Influence on Immune System Development. In addition to its direct effects on the immune system, *P. falciparum* can also influence the development and function of the immune system, particularly in young children and during pregnancy. Chronic infections and repeated exposure to the parasite can affect the maturation of the immune system, potentially leading to altered immune responses in the long term. This impact on immune system development can have implications for susceptibility to future infections and the overall effectiveness of immune responses.[46-50]

Role of Cytokines in Malaria During Pregnancy

Cytokines are crucial mediators of the immune response and play significant roles in the pathogenesis of malaria during pregnancy. Their production and regulation are essential for maintaining the balance between an effective immune response and minimizing excessive inflammation that can harm both the mother and the fetus. The roles of cytokines in malaria during pregnancy involve both protective and detrimental effects, influencing disease severity, pregnancy outcomes, and overall maternal and fetal health. Pro-inflammatory cytokines, such as tumor

necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and interleukin-1β (IL-1β), are pivotal in the immune response to *Plasmodium falciparum* infection. These cytokines are produced by various immune cells, including macrophages, T cells, and natural killer (NK) cells, and are involved in the activation of the innate and adaptive immune responses. During malaria infection, elevated levels of TNF-α and IFN-γ are associated with the inflammatory response and the recruitment of immune cells to the site of infection. While pro-inflammatory cytokines are crucial for controlling malaria, their excessive production can lead to severe complications. In pregnant women, high levels of TNF-α and IFN-γ can contribute to placental inflammation, impaired blood flow, and disruption of placental function. This inflammation can adversely affect fetal development, leading to outcomes such as low birth weight (LBW) and preterm delivery. Additionally, the overproduction of pro-inflammatory cytokines can exacerbate maternal anemia and contribute to the overall severity of malaria.[51-55]

Anti-inflammatory cytokines, such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), play a role in modulating the immune response to *P. falciparum* infection. These cytokines are produced to counterbalance the effects of pro-inflammatory cytokines and prevent excessive inflammation. IL-10, in particular, helps to downregulate the production of pro-inflammatory cytokines and supports the development of regulatory T cells (Tregs) that are involved in maintaining immune tolerance. During pregnancy, the increase in anti-inflammatory cytokines is part of the physiological shift towards a more tolerant immune environment. While this shift helps to protect the fetus, it can also impact the maternal immune response to malaria. Elevated levels of IL-10 and TGF-β can impair the ability of the immune system to clear the infection effectively, leading to persistent malaria and increased risk of complications. The balance between pro-inflammatory and anti-inflammatory cytokines is critical for achieving an optimal immune response during pregnancy. The balance between pro-inflammatory and anti-inflammatory cytokines is crucial for determining the outcome of malaria during pregnancy. An imbalance, characterized by excessive pro-inflammatory cytokines or inadequate anti-inflammatory responses, can lead to adverse pregnancy outcomes. For example, excessive TNF-α and IFN-γ can contribute to severe placental malaria, which is associated with increased risks of LBW, preterm delivery, and fetal growth restriction. Conversely, an overactive anti-inflammatory response can impair parasite clearance and prolong the infection. The presence of placental malaria further complicates the cytokine milieu. Infected erythrocytes adhere to the placental tissue, leading to localized inflammation and the production of cytokines that can affect both maternal and fetal health. The immune response in the placenta involves a complex network of cytokines and immune cells that can either help control the infection or exacerbate placental damage. Interventions that modulate cytokine responses, such as the use of anti-inflammatory agents or cytokine inhibitors, could potentially reduce the adverse effects of malaria. Additionally, strategies that balance the immune response, such as intermittent preventive treatment in pregnancy (IPTp) and the use of insecticide-treated bed nets (ITNs), are crucial for preventing malaria and its associated complications. Vaccines targeting specific antigens associated with placental malaria, such as VAR2CSA, are another promising approach. These vaccines aim to induce a robust immune response that can prevent the adhesion of infected erythrocytes to the placenta, thereby reducing inflammation and improving pregnancy outcomes. A deeper understanding of cytokine

roles and interactions in malaria during pregnancy can inform the development of these and other interventions.[56-65]

Placental Malaria and Immune Responses

Placental malaria, characterized by the sequestration of *Plasmodium falciparum*-infected red blood cells (RBCs) in the placenta, is a serious complication of malaria during pregnancy. It significantly impacts both maternal and fetal health, leading to adverse outcomes such as low birth weight (LBW), preterm delivery, and increased perinatal mortality. The immune responses to placental malaria are complex and involve interactions between the parasite, the placenta, and the maternal immune system. In placental malaria, infected RBCs adhere to the placental syncytiotrophoblasts through specific adhesion molecules, primarily VAR2CSA. This adhesion is mediated by the expression of variant surface antigens (VSAs) on the surface of infected RBCs, which interact with chondroitin sulfate A (CSA) receptors in the placenta. This interaction facilitates the sequestration of infected RBCs in the placenta, leading to localized inflammation and disruption of placental function. The adherence of these cells to the placenta helps the parasite evade systemic immune responses and persist in a niche where it can continue to replicate. The maternal immune response to placental malaria involves a range of immune cells and cytokines. Infected placentas often exhibit localized inflammation characterized by the presence of immune cells such as macrophages, dendritic cells, and T lymphocytes. These cells produce cytokines and chemokines that can either help control the infection or contribute to placental damage. Pro-inflammatory cytokines, including TNF-α, IFN-γ, and IL-1β, are commonly elevated in cases of placental malaria. While these cytokines are essential for mounting an effective immune response, their excessive production can lead to detrimental effects on the placenta. High levels of TNF-α, for example, are associated with impaired placental blood flow and increased risk of LBW and preterm delivery. The inflammatory environment can disrupt the normal function of the placenta, leading to reduced nutrient and oxygen transfer to the fetus.[66-70]

The placenta itself plays a critical role in the immune response to malaria. It is composed of various cell types, including trophoblasts, which can interact with immune cells and cytokines. The syncytiotrophoblasts, which line the maternal-fetal interface, can secrete cytokines and express surface molecules that influence immune cell recruitment and activation. Infected placentas often show increased expression of adhesion molecules and inflammatory mediators, contributing to the recruitment of immune cells and the establishment of a localized inflammatory response. In addition to the inflammatory response, the placenta also exhibits mechanisms of immune tolerance to prevent fetal rejection. During malaria infection, this tolerance can be compromised, leading to an exaggerated immune response that further impacts placental function. The balance between immune activation and tolerance is crucial for maintaining a healthy pregnancy and managing placental malaria. The immune responses in placental malaria can have significant implications for pregnancy outcomes. The inflammatory cytokines and immune cells involved in the response can impair placental function, leading to complications such as LBW, preterm birth, and fetal growth restriction. The disruption of placental function affects the delivery of nutrients and oxygen to the fetus, which can result in poor neonatal outcomes. Additionally, the immune response to

placental malaria can influence maternal health. Chronic inflammation and the associated immune responses can exacerbate maternal anemia and contribute to overall disease severity. The interplay between maternal and placental immune responses is complex, and disruptions in this balance can lead to adverse effects on both the mother and the fetus.[70-75]

Interventions and Future Directions

Maternal immunity plays a pivotal role in determining the outcome of malaria during pregnancy. The immune system of pregnant women undergoes significant changes to accommodate the developing fetus, which is genetically distinct from the mother. These changes can impact susceptibility to malaria and influence disease severity. Pregnancy induces a unique immune environment designed to balance the need for immune tolerance of the fetus with the necessity of defending against infections. The maternal immune system undergoes shifts in cytokine production, immune cell populations, and overall immune function. These adaptations include an increased production of anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), which help to prevent excessive inflammation and fetal rejection. The expansion of regulatory T cells (Tregs) during pregnancy is another critical adaptation. Tregs play a role in maintaining immune tolerance by suppressing excessive immune responses. This expansion helps protect the fetus but can also impair the maternal immune system's ability to respond effectively to infections like malaria. The balance between immune tolerance and immune activation is crucial for managing the effects of malaria during pregnancy. The altered immune environment during pregnancy affects the maternal response to *Plasmodium falciparum* infection. Pregnant women are more susceptible to malaria compared to non-pregnant women, particularly during their first pregnancy (primigravidae). This increased susceptibility is partly due to the immunological changes that create a more favorable environment for the parasite. The compromised immune response in pregnant women can lead to increased severity of malaria, including higher rates of maternal anemia and more severe placental malaria. The interaction between the parasite and the maternal immune system can also contribute to adverse pregnancy outcomes such as low birth weight (LBW) and preterm delivery. The chronic inflammation associated with malaria can impair placental function, affecting nutrient and oxygen delivery to the fetus.[76-80]

Plasmodium falciparum employs several strategies to evade the maternal immune system. The expression of variant surface antigens (VSAs) on the surface of infected red blood cells (RBCs) allows the parasite to undergo antigenic variation, avoiding detection by the immune system. The adherence of infected RBCs to the placenta via molecules such as VAR2CSA further helps the parasite evade immune surveillance. The parasite's ability to sequester in the placenta means it can avoid being cleared by the spleen, which is responsible for filtering and destroying abnormal or infected RBCs. This sequestration results in chronic infection and prolonged exposure to the maternal immune system, which can exacerbate disease severity and contribute to complications. Maternal immunity to malaria is influenced by previous exposure to the parasite and parity. Women with multiple pregnancies (multigravidae) often develop partial immunity due to repeated exposure and the acquisition of specific antibodies against placental antigens. This acquired

immunity helps protect against severe outcomes and improves the maternal response to subsequent infections. In contrast, primigravidae, who are experiencing their first pregnancy, are generally more susceptible to malaria and its complications. They lack the protective antibodies and immune adaptations that develop with repeated exposure. This increased susceptibility highlights the importance of targeted interventions for first-time pregnant women.[81-83]

Public Health Interventions

Strategies such as intermittent preventive treatment in pregnancy (IPTp) with antimalarial drugs, the use of insecticide-treated bed nets (ITNs), and prompt treatment of malaria infections are essential for protecting pregnant women from malaria. The immunological implications of malaria during pregnancy underscore the need for tailored interventions that account for the unique immune environment and its impact on disease progression. Effective interventions must consider the complex interplay between the maternal immune system, the *Plasmodium falciparum* parasite, and the specific challenges posed by pregnancy. Understanding these interactions can enhance the development and implementation of strategies to prevent and manage malaria in pregnant women. Antimalarial treatments are crucial in managing malaria during pregnancy, but their efficacy can be influenced by the maternal immune response. Current strategies, such as intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP), are designed to reduce the incidence of malaria and its complications. IPTp aims to provide protective levels of antimalarial drugs at regular intervals, effectively reducing parasite prevalence and preventing severe outcomes. However, the effectiveness of IPTp can be affected by the altered immune environment in pregnant women, including shifts in cytokine production and immune cell function. Research into optimizing dosing regimens and combining antimalarial drugs with immune-modulating agents could enhance treatment outcomes. Additionally, the development of new antimalarial drugs that specifically target the placental stage of *P. falciparum* could improve efficacy and reduce the risk of drug resistance.[84-86]

Vaccination is a promising approach for preventing malaria, especially in the context of pregnancy. The development of vaccines targeting specific antigens, such as the VAR2CSA antigen, aims to induce protective immune responses against placental malaria. These vaccines seek to prevent the adhesion of infected RBCs to the placenta, thereby reducing inflammation and improving pregnancy outcomes. For example, vaccines must be designed to elicit robust and durable immune responses in the altered immune environment of pregnant women. Research into adjuvants and vaccine delivery systems that enhance immune responses without inducing excessive inflammation is essential for optimizing vaccine effectiveness. Insecticide-treated bed nets (ITNs) are a key preventive measure against malaria. They protect individuals from mosquito bites and reduce the transmission of *Plasmodium falciparum*. For pregnant women, ITNs help reduce the risk of malaria and its complications by decreasing exposure to malaria vectors.

The effectiveness of ITNs can be influenced by the maternal immune system, including changes in cytokine levels and immune cell populations. Ensuring high coverage and consistent use of ITNs is vital for achieving optimal protection. Additionally, ongoing research into improving the

efficacy and durability of insecticides used in bed nets could enhance their impact in preventing malaria during pregnancy.[87-88]

The immune modulation associated with pregnancy can impact the effectiveness of malaria interventions. Strategies that modulate immune responses, such as the use of anti-inflammatory agents or immune-modulating drugs, may help improve the maternal immune response to *P. falciparum*. Balancing immune tolerance and activation is crucial for managing malaria during pregnancy without compromising fetal health. Research into immune modulators that can enhance the maternal response to malaria while minimizing adverse effects is an area of interest. Such interventions could complement existing antimalarial treatments and preventive measures, providing a more comprehensive approach to managing malaria during pregnancy. Personalized approaches to prevention and treatment are becoming increasingly important in addressing the unique needs of pregnant women with malaria. Factors such as parity, previous exposure to malaria, and individual immune responses can influence susceptibility and disease outcomes. Tailoring interventions based on these factors can enhance their effectiveness. For example, primigravidae may require more intensive preventive measures compared to multigravidae, who may have acquired partial immunity. Personalized treatment strategies that account for the individual's immune profile and pregnancy status can improve outcomes and reduce the risk of severe complications.[89]

Integrating malaria prevention and treatment with broader maternal health services is essential for improving outcomes. Regular antenatal care provides an opportunity for screening, monitoring, and managing malaria, as well as addressing other aspects of maternal health. Coordinating malaria interventions with other maternal health services, such as nutritional support and management of anemia, can enhance overall health outcomes. Ensuring that malaria prevention and treatment are part of comprehensive maternal care programs can improve both maternal and fetal health. Education and behavior change are critical components of malaria prevention during pregnancy. Increasing awareness about the importance of ITNs, IPTp, and early treatment of malaria can improve adherence to preventive measures and treatment guidelines. Public health campaigns and community-based interventions that educate pregnant women about malaria and promote safe practices are essential for reducing the incidence of malaria. Engaging healthcare providers in delivering consistent messages and support can further enhance the impact of malaria interventions.[89]

Conclusion

Malaria during pregnancy presents a complex challenge with profound implications for both maternal and fetal health. The interplay between *Plasmodium falciparum*, the altered maternal immune system, and the placental environment shapes the course and severity of the disease. Effective management requires a multifaceted approach that integrates understanding of immunological mechanisms with targeted interventions. The maternal immune response to malaria is significantly influenced by pregnancy-induced changes that can affect susceptibility and disease outcomes. These changes, including shifts in cytokine production and immune cell function, create

a unique immunological landscape that impacts how the body responds to *P. falciparum* infection. The parasite's ability to evade the immune system through antigenic variation and adherence to the placenta further complicates treatment and prevention efforts.

Current interventions, such as intermittent preventive treatment in pregnancy (IPTp), insecticide-treated bed nets (ITNs), and prompt antimalarial treatment, are vital for reducing the incidence and severity of malaria. However, the effectiveness of these measures can be influenced by the maternal immune environment and the parasite's evasion strategies. Advancements in vaccine development, aimed at preventing placental malaria and inducing protective immune responses, hold promise for improving outcomes. Personalized approaches that consider factors such as maternal parity and previous exposure, along with integrated maternal health services, can enhance the impact of interventions. Continued research into the mechanisms of immune response, novel therapeutic options, and public health strategies will be crucial for addressing this critical health issue.

References

1. Uneke CJ. Impact of placental Plasmodium falciparum malaria on pregnancy and perinatal outcome in sub-Saharan Africa: part III: placental malaria, maternal health, and public health. The Yale journal of biology and medicine. 2008;81(1):1.
2. Gontie GB, Wolde HF, Baraki AG. Prevalence and associated factors of malaria among pregnant women in Sherkole district, Benishangul Gumuz regional state, West Ethiopia. BMC Infectious Diseases. 2020; 20:1-8.
3. Obeagu EI, Agreen FC. Anaemia among pregnant women: A review of African pregnant teenagers. J Pub Health Nutri. 2023; 6 (1). 2023;138. links/63da799664fc860638054562/Anaemia-among-pregnant-women-A-review-of-African-pregnant-teenagers.pdf.
4. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-8. links/5710fae108ae846f4ef05afb/ERYTHROPOIETIN-IN-THE-ANAEMIAS-OF-PREGNANCY-A-REVIEW.pdf.
5. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021;9(4):145-8. links/608a6728a6fdccaebdf52d94/Assessment-of-Haematological-Changes-in-Pregnant-Women-of-Ido-Ondo.pdf.
6. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 ;6(2):10-3. http://irmhs.com/index.php/irmhs/article/view/111.
7. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.

Citation: Obeagu EI, Obeagu GU. Malaria in Pregnancy: Insights into Immunological Responses. Elite Journal of Immunology, 2024; 2(6): 26-43

8. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of Protein C, Protein S and Fibrinogen of Pregnant Women with Malaria in Owerri Metropolis. Madonna University journal of Medicine and Health Sciences. 2022;2(2):1-9.
9. Bonilla FA, Oettgen HC. Adaptive immunity. Journal of Allergy and Clinical Immunology. 2010;125(2): S33-40.
10. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. EVALUATION OF PROTEIN C, PROTEIN S AND FIBRINOGEN OF PREGNANT WOMEN WITH MALARIA IN OWERRI METROPOLIS. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022;2(2):1-9.
11. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.
12. Feeney ME. The immune response to malaria in utero. Immunological reviews. 2020 ;293(1):216-229.
13. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine. 2023;102(46): e36166.
14. Obeagu EI, Chijioke UO, Ekelozie IS. Malaria rapid diagnostic test (RDTs). Ann Clin Lab Res. 2018;6(4):275.
15. Ogomaka IA, Obeagu EI. Methods of Breast Feeding as Determinants of Malaria Infections among Babies in IMO State, Nigeria. International Journal of Medical Science and Dental Research. 2019;2(01):17-24.
16. Obeagu EI, Ikpenwa JN, Chukwueze CM, Obeagu GU. Evaluation of protein C, protein S and fibrinogen of pregnant women in Owerri Metropolis. Madonna University Journal of Medicine and Health Sciences. 2022;2(1):292-8. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/57.
17. Obeagu EI, Obeagu GU, Adepoju OJ. Evaluation of haematological parameters of pregnant women based on age groups in Olorunsogo road area of Ido, Ondo state. J. Bio. Innov11 (3). 2022:936-941.
18. Obeagu EI, Obeagu GU, Egba SI, Emeka-Obi OR. Combatting Anemia in Pediatric Malaria: Effective Management Strategies. Int. J. Curr. Res. Med. Sci. 2023;9(11):1-7.
19. Hassan AO, Oso OV, Obeagu EI, Adeyemo AT. Malaria Vaccine: Prospects and Challenges. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022;2(2):22-40.
20. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-9.
21. Moya-Alvarez V, Abellana R, Cot M. Pregnancy-associated malaria and malaria in infants: an old problem with present consequences. Malaria journal. 2014; 13:1-10.
22. Obeagu EI. An update on utilization of antenatal care among pregnant Women in Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2022;9(9): 21-6.DOI: 10.22192/ijcrcps.2022.09.09.003
23. Okoroiwu IL, Obeagu EI, Obeagu GU. Determination of clot retraction in preganant women attending antenatal clinic in federal medical centre Owerri, Nigeria. Madonna

University Journal of Medicine and Health Sciences. 2022;2(2):91-97. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/67.

24. Obeagu EI, Hassan AO, Adepoju OJ, Obeagu GU, Okafor CJ. Evaluation of Changes in Haematological Parameters of Pregnant Women Based on Gestational Age at Olorunsogo Road Area of Ido, Ondo State. Nigeria. Journal of Research in Medical and Dental Science. 2021;9(12):462-.links/61b1e32f0c4bfb675178bfa7/Evaluation-of-Changes-in-Haematological-Parameters-of-Pregnant-Women-Based-on-Gestational-Age-at-Olorunsogo-Road-Area-of-Ido-Ondo-State-Nigeria.pdf.
25. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Irondi EA, Arinze-Anyiam OC, Asiyah MK. ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. International Journal of Research and Reports in Hematology. 2022 Jun 21;5(2):113-121.
26. Obeagu EI. Gestational Thrombocytopaenia. J Gynecol Women's Health. 2023;25(3):556163. links/64b01aa88de7ed28ba95fccb/Gestational-Thrombocytopaenia.pdf.
27. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
28. Dobaño C, Berthoud T, Manaca MN, Nhabomba A, Guinovart C, Aguilar R, Barbosa A, Groves P, Rodríguez MH, Jimenez A, Quimice LM. High production of pro-inflammatory cytokines by maternal blood mononuclear cells is associated with reduced maternal malaria but increased cord blood infection. Malaria Journal. 2018; 17:1-3.
29. Obeagu EI, Busari AI, Uduchi IO, Ogomaka IA, Ibekwe AM, Vincent CC, Chijioke UO, Okafor CJ, Okoroiwu HU, Adike CN. Age-Related Haematological Variations in Patients with Asymptomatic Malaria in Akure, Ondo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(42B):218-24.
30. Ogomaka IA, Obeagu EI. Malaria in Pregnancy Amidst Possession of Insecticide Treated Bed Nets (ITNs) in Orlu LGA of Imo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(41B):380-386.
31. Ogbonna CO, Obeagu EI, Ufelle SA, Ogbonna LN. Evaluation of haematological alterations in children infected by Plasmodium falciparum Species in Enugu, Enugu State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(1):38-45.
32. Appay V. The physiological role of cytotoxic CD4+ T-cells: the holy grail? Clinical & Experimental Immunology. 2004;138(1):10-13.
33. Okorie HM, Obeagu EI, Obarezi HC, Anyiam AF. Assessment of some inflammatory cytokines in malaria infected pregnant women in Imo State Nigeria. International Journal of Medical Science and Dental Research. 2019;2(1):25-36.
34. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of some haematological parameters in malaria infected pregnant women in Imo state Nigeria. Int. J. Curr. Res. Biol. Med. 2018;3(9):1-4.
35. Nwosu DC, Obeagu EI, Ezenwuba C, Agu GC, Amah H, Ozims SJ, Nwanjo HU, Edward A, Izuchukwu IF, Amadike JN, Nwagwu AJ. Antioxidant status of children with

Plasmodium falciparum malaria in Owerri municipal council of Imo state. Int. J. Curr. Res. Chem. Pharm. Sci. 2016;3(8):40-46.
36. Harrington WE, Kakuru A, Jagannathan P. Malaria in pregnancy shapes the development of foetal and infant immunity. Parasite immunology. 2019;41(3): e12573.
37. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research. 2017;5(4):206.
38. Anyiam AF, Arinze-Anyiam OC, Omosigho PO, Ibrahim M, Irondi EA, Obeagu EI, Obi E. Blood Group, Genotype, Malaria, Blood Pressure and Blood Glucose Screening Among Selected Adults of a Community in Kwara State: Implications to Public Health. Asian Hematology Research Journal. 2022;6(3):9-17.
39. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15.
40. Offie DC, Ibekwe AM, Agu CC, Esimai BN, Okpala PU, Obeagu EI, Ufelle SA, Ogbonna LN. Fibrinogen and C-Reactive Protein Significance in Children Infected by Plasmodium falciparum Species in Enugu, Enugu State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(15):1-8.
41. Obeagu EI, Ogunnaya FU. PREGNANCYINDUCED HAEMATOLOGICAL CHANGES: A KEY TO MARTERNAL AND CHILD HEALTH. European Journal of Biomedical. 2023;10(8):42-43. links/64c890bddb38b20d6dad2c5c/PREGNANCY-INDUCED-HAEMATOLOGICAL-CHANGES-A-KEY-TO-MARTERNAL-AND-CHILD-HEALTH.pdf
42. Obeagu EI, Ofodile AC, Okwuanaso CB. A review of urinary tract infections in pregnant women: Risks factors. J Pub Health Nutri. 2023; 6 (1). 2023; 137:26-35. links/63c3a9116fe15d6a571e8bba/A-review-of-urinary-tract-infections-in-pregnant-women-Risks-factors.pdf.
43. Obeagu EI, Obeagu GU, Musiimenta E. Post partum haemorrhage among pregnant women: Update on risks factors. Int. J. Curr. Res. Med. Sci. 2023;9(2): 14-17.DOI: 10.22192/ijcrms.2023.09.02.003
44. Obeagu EI, Obeagu GU, Ogunnaya FU. Deep vein thrombosis in pregnancy: A review of prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8): 14-21.DOI: 10.22192/ijcrcps.2023.10.08.002
45. Arama C, Quin JE, Kouriba B, Östlund Farrants AK, Troye-Blomberg M, Doumbo OK. Epigenetics and malaria susceptibility/protection: A missing piece of the puzzle. Frontiers in Immunology. 2018; 9:1733.
46. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of some haematological parameters in malaria infected pregnant women in Imo state Nigeria. Int. J. Curr. Res. Biol. Med. 2018;3(9): 1-4.DOI: 10.22192/ijcrbm.2018.03.09.001
47. Onyenweaku FC, Amah HC, Obeagu EI, Nwandikor UU, Onwuasoanya UF. Prevalence of asymptomatic bacteriuria and its antibiotic susceptibility pattern in pregnant women

attending private ante natal clinics in Umuahia Metropolitan. Int J Curr Res Biol Med. 2017;2(2): 13-23.DOI: 10.22192/ijcrbm.2017.02.02.003
48. Okoroiwu IL, Chinedu-Madu JU, Obeagu EI, Vincent CC, Ochiabuto OM, Ibekwe AM, Amaechi CO, Agu CC, Anoh NV, Amadi NM. Evaluation of Iron Status, Haemoglobin and Protein Levels of Pregnant Women in Owerri Metropolis. Journal of Pharmaceutical Research International. 2021;33(27A):36-43.
49. Obeagu EI, Njar VE, Obeagu GU. Infertility: Prevalence and Consequences. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(7):43-50.
50. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. Journal of Pharmaceutical Research International. 2021;33(42A):53-65.
51. Broen K, Brustoski K, Engelmann I, Luty AJ. Placental Plasmodium falciparum infection: causes and consequences of in utero sensitization to parasite antigens. Molecular and biochemical parasitology. 2007;151(1):1-8.
52. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of coagulation parameters in malaria infected pregnant women in Imo state, Nigeria. International Journal of Current Research in Medical Sciences. 2018;4(9):41-49.
53. Ogbonna LN, Ezeoru VC, Ofodile AC, Ochiabuto OM, Obi-Ezeani CN, Okpala PU, Okafor CJ, Obeagu GU, Busari AI, Obeagu EI. Gender Based Variations of Haematological Parameters of Patients with Asymptomatic Malaria in Akure, Ondo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(8):75-80.
54. Eberendu IF, Ozims SJ, Agu GC, Amah HC, Obasi CC, Obioma-Elemba JE, Ihekaire DE, Ibanga IE, Amah CC, Obeagu EI, Nwosu DC. Impact of human activities on the breeding of mosquitoes of human disease in Owerri metropolis, Imo state. Int J Adv Res Biol Sci IJARBS. 2017;4(12):98-106.
55. Obeagu EI, Ofodile AC, Okwuanaso CB. A review on socio economic and behavioral aspects of malaria and its control among children under 5 years of age in Africa. J Pub Health Nutri. 2023; 6 (1): 136.
56. Djontu JC, Siewe Siewe S, Mpeke Edene YD, Nana BC, Chomga Foko EV, Bigoga JD, Leke RF, Megnekou R. Impact of placental Plasmodium falciparum malaria infection on the Cameroonian maternal and neonate's plasma levels of some cytokines known to regulate T cells differentiation and function. Malaria journal. 2016; 15:1-1.
57. Obeagu EI, Faduma MH, Uzoma G. Ectopic Pregnancy: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4): 40-4.DOI: 10.22192/ijcrcps.2023.10.04.004
58. Obeagu EI, Gamade SM, Obeagu GU. The roles of Neutrophils in pregnancy. Int. J. Curr. Res. Med. Sci. 2023;9(5): 31-35.DOI: 10.22192/ijcrms.2023.09.05.005
59. Obeagu EI, Obeagu GU. Molar Pregnancy: Update of prevalence and risk factors. Int. J. Curr. Res. Med. Sci. 2023;9(7): 25-28.DOI: 10.22192/ijcrms.2023.09.07.005
60. Kabyemela E, Gonçalves BP, Prevots DR, Morrison R, Harrington W, Gwamaka M, Kurtis JD, Fried M, Duffy PE. Cytokine profiles at birth predict malaria severity during infancy. PloS one. 2013;8(10):e77214.
61. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Barriers to utilization of maternal health services

in southern senatorial district of Cross Rivers state, Nigeria. International Journal of Advanced Multidisciplinary Research. 2017;4(8): 1-9.DOI: 10.22192/ijamr.2017.04.08.001

62. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
63. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of coagulation parameters in malaria infected pregnant women in Imo state, Nigeria. International Journal of Current Research in Medical Sciences. 2018;4(9): 41-9.DOI: 10.22192/ijcrms.2018.04.09.006
64. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8): 22-6.DOI: 10.22192/ijcrcps.2023.10.08.003
65. Obeagu E, Eze RI, Obeagu EI, Nnatuanya IN, Dara EC. ZINC LEVEL IN APPARENTLY PREGNANT WOMEN IN URBAN AREA. Madonna University journal of Medicine and Health Sciences. 2022;2(1):134-48. https://www.journal.madonnauniversity.edu.ng/index.php/medicine/article/view/40.
66. Ogomaka IA, Obeagu EI. Malaria in Pregnancy Amidst Possession of Insecticide Treated Bed Nets (ITNs) in Orlu LGA of Imo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(41B):380-386.
67. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. SICKLE CELL ANAEMIA: A GESTATIONAL ENIGMA. migration. 2023; 17:18.
68. Harrington WE, Kakuru A, Jagannathan P. Malaria in pregnancy shapes the development of foetal and infant immunity. Parasite immunology. 2019;41(3):e12573.
69. Ifeanyi OE, Uzoma OG. A review on erythropietin in pregnancy. J. Gynecol. Womens Health. 2018;8(3):1-4. https://www.academia.edu/download/56538560/A_Review_on_Erythropietin_in_Pregnancy.pdf.
70. Ifeanyi OE. A review on pregnancy and haematology. Int. J. Curr. Res. Biol. Med. 2018;3(5): 26-8.DOI: 10.22192/ijcrbm.2018.03.05.006
71. Nwosu DC, Nwanjo HU, Obeagu EI, Ibebuike JE, Ezeama MC. Ihekireh. Changes in liver enzymes and lipid profile of pregnant women with malaria in Owerri, Nigeria. International Journal of Current Research and Academic Review. 2015;3(5):376-383.
72. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Factors that influence women's utilization of primary health care services in Calabar Cros river state, Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2017;4(7):28-33.
73. Elemchukwu Q, Obeagu EI, Ochei KC. Prevalence of Anaemia among Pregnant Women in Braithwaite Memorial Specialist Hospital (BMSH) Port Harcourt. IOSR Journal of Pharmacy and Biological Sciences. 2014;9(5):59-64.
74. Natama HM, Moncunill G, Rovira-Vallbona E, Sanz H, Sorgho H, Aguilar R, Coulibaly-Traoré M, Somé MA, Scott S, Valéa I, Mens PF. Modulation of innate immune responses

at birth by prenatal malaria exposure and association with malaria risk during the first year of life. BMC medicine. 2018; 16:1-5.
75. Akandinda M, Obeagu EI, Katonera MT. Non Governmental Organizations and Women's Health Empowerment in Uganda: A Review. Asian Research Journal of Gynaecology and Obstetrics. 2022;8(3):12-26.
76. Gamde MS, Obeagu EI. IRON DEFICIENCY ANAEMIA: ENEMICAL TO PREGNANCY. European Journal of Biomedical. 2023;10(9):272-275. links/64f63358827074313ffaae7b/IRON-DEFICIENCY-ANAEMIA-ENEMICAL-TO-PREGNANCY.pdf.
77. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. Journal of Pharmaceutical Research International. 2021;33(42A):53-65.
78. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Studies of Some Haemostatic Variables in Preeclamptic Women in Owerri, Imo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(42B):39-48.
79. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8):22-26.
80. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023;6(2):10-13.
81. Mutabingwa TK, Bolla MC, Li JL, Domingo GJ, Li X, Fried M, Duffy PE. Maternal malaria and gravidity interact to modify infant susceptibility to malaria. PLoS medicine. 2005;2(12):e407.
82. Gamble C, Ekwaru PJ, Garner P, Ter Kuile FO. Insecticide-treated nets for the prevention of malaria in pregnancy: a systematic review of randomised controlled trials. PLoS medicine. 2007;4(3):e107.
83. Okoko BJ, Enwere G, Ota MO. The epidemiology and consequences of maternal malaria: a review of immunological basis. Acta tropica. 2003;87(2):193-205.
84. Dobaño C, Berthoud T, Manaca MN, Nhabomba A, Guinovart C, Aguilar R, Barbosa A, Groves P, Rodríguez MH, Jimenez A, Quimice LM. High production of pro-inflammatory cytokines by maternal blood mononuclear cells is associated with reduced maternal malaria but increased cord blood infection. Malaria Journal. 2018; 17:1-3.
85. Umbers AJ, Stanisic DI, Ome M, Wangnapi R, Hanieh S, Unger HW, Robinson LJ, Lufele E, Baiwog F, Siba PM, King CL. Does malaria affect placental development? Evidence from in vitro models. PLoS One. 2013;8(1):e55269.
86. Arama C, Quin JE, Kouriba B, Östlund Farrants AK, Troye-Blomberg M, Doumbo OK. Epigenetics and malaria susceptibility/protection: A missing piece of the puzzle. Frontiers in Immunology. 2018; 9:1733.
87. Gbedande K, Carpio VH, Stephens R. Using two phases of the CD 4 T cell response to blood-stage murine malaria to understand regulation of systemic immunity and placental pathology in Plasmodium falciparum infection. Immunological reviews. 2020;293(1):88-114.

Citation: Obeagu EI, Obeagu GU. Malaria in Pregnancy: Insights into Immunological Responses**.** Elite Journal of Immunology, 2024; 2(6): 26-43

88. Lindsay SW, Thomas MB, Kleinschmidt I. Threats to the effectiveness of insecticide-treated bednets for malaria control: thinking beyond insecticide resistance. The Lancet Global Health. 2021;9(9):e1325-1331.
89. Akinleye SO, Falade CO, Ajayi IO. Knowledge and utilization of intermittent preventive treatment for malaria among pregnant women attending antenatal clinics in primary health care centers in rural southwest, Nigeria: a cross-sectional study. BMC pregnancy and childbirth. 2009; 9:1-9.

Citation: Obeagu EI, Obeagu GU. Malaria in Pregnancy: Insights into Immunological Responses**.** Elite Journal of Immunology, 2024; 2(6): 26-43